Netflix Stock Price Soars After Earnings Report Record New Memberships
Netflix stock price ( NASDAQ: NFLX ) is up more than 13% in the after-hours following its release of the fourth-quarter earnings report for fiscal year 2024. The streaming company recorded a 16% increase in revenue year-over-year, reaching 19% on a foreign exchange (F/X) neutral basis, which the
If you invested $1000 in Chipotle Mexican Grill (NYSE:CMG) 5 years ago, here's how much it's worth today
They say, “If it looks like a restaurant, cooks food like a restaurant, and serves food like a restaurant, then it’s probably a restaurant.”. However, this might not be how investors see Chipotle Mexican Grill ( NYSE:CMG ). Chipotle’s stock is currently trading at a P/E ratio of around 54, while many
Dr. Wendell Bulmer Scholarship Invites Nationwide Undergraduate Applications for 2026 Award Honoring Patient-Centered Medicine
Newsfile
1 hours ago
Tampa, Florida--(Newsfile Corp. - March 30, 2026) - The Dr. Wendell Bulmer Scholarship for Future Physicians officially opens its 2026 application cycle, offering undergraduate students across the United States an opportunity to receive financial sup
Tsodilo Resources Ltd Announces Strategic Collaboration with Battelle Memorial Institute to Advance Critical Minerals and Rare Earth Element Exploration
Newsfile
2 hours ago
Toronto, Ontario--(Newsfile Corp. - March 30, 2026) - Tsodilo Resources Ltd. (TSXV: TSD) (OTCQB: TSDRF) (FSE: TZO) ("Tsodilo" or the "Company") is pleased to announce a strategic collaboration with Battelle Memorial Institute ("Battelle") to apply ar
Ivanhoe Mines to Issue Kamoa-Kakula Updated Technical Report After Market Close on March 31, 2026 and Host a Conference Call for Investors on the Same Day at 4:30pm EST
Newsfile
2 hours ago
London, United Kingdom--(Newsfile Corp. - March 29, 2026) - Ivanhoe Mines (TSX: IVN) (OTCQX: IVPAF) will file the updated Kamoa-Kakula technical report and issue a press release summarizing the report shortly after market close on Tuesday, March 31,
Sigma Lithium Announces 2025 Full Year Earnings Presentation Call on March 30 at 7:30 AM EST
Newsfile
10 hours ago
SUMMARYEvent Title: Sigma Lithium Fourth Quarter 2025 Earnings Results CallEvent Date: March 30, 2026Start Time: 7:30 a.m. ESTAttendee URL: https://mzgroup.zoom.us/webinar/register/WN_-yfOrvFmTCqtQXGv6fVr5gSão Paulo, Brazil--(Newsfile Corp. - March 2
Skychain Technologies Inc. Provides Update on Financial Position, Asset Status, and Ongoing Transition Issues
Newsfile
Yesterday at 2:06 AM GMT
Vancouver, British Columbia--(Newsfile Corp. - March 28, 2026) - Skychain Technologies Inc. (TSXV: SCT.H) (the "Company" or "Skychain") provides a further update regarding its financial position, asset status, and the ongoing transition to the board
New $150,000 Audiophile System by Future Audiophile Helps Harvard Students Creatively Deal with Stress and Anxiety Through Audiophile Sound
Newsfile
Yesterday at 12:54 AM GMT
FutureAudiophile.com has donated a sound system to Harvard's Shelemay Audio Lab offering a drug-free, measurable way for students to creatively lower stress levels.Los Angeles, California--(Newsfile Corp. - March 28, 2026) - Thanks to the magazine an
Dermatology Online Discussion Forum Named Top Forum for 2026
Newsfile
Yesterday at 12:51 AM GMT
The Dermatology Online Discussion Forum was recognized as a top dermatology discussion forum for dermatologists in 2026, highlighting its role in fostering timely, peer-driven collaboration and advancing global professional engagement in dermatologyD
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
GlobeNewswire Inc.
Mar 28, 2026 7:00 PM GMT
In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving clear / almost clear skinFollowing positive Phase 2 LI
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
GlobeNewswire Inc.
Mar 28, 2026 7:00 PM GMT
The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing potential of brepocitinib 30 mg once-daily in dermatomyositisBrepocitinib 30 mg was superior to placebo on the primary an
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
GlobeNewswire Inc.
Mar 28, 2026 5:30 PM GMT
Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality‑of‑life improvements and itch relief emerged ahead of PASI 90 skin clearance, an
